Fate Therapeutics (FATE) Tops Q3 EPS by 3c

Fate Therapeutics (NASDAQ: FATE) reported Q3 EPS of ($0.27), $0.03 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $1.74 million versus the consensus estimate of $1.36 million.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Rubio says Iran cannot charge tolls in Strait of Hormuz
• Pelican Way Research shorts Hyliion Holdings (HYLN) on VFG deal concerns